- New patent approved for the United States
- Protection until 2031 for the industrial manufacturing process of the drug candidate QGC001
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company whose purpose is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, is announcing a new patent that has just been approved for the United States (no. 9187418), along with two other similar patents for Mexico (no. 222939) and Eurasia (no. 021612).
These patents, for which the international application was submitted in October 2011, protect the industrial manufacturing process of the main active ingredient of the drug candidate QGC001 until 2031. Similar patents have already been granted for New Zealand and South Africa.
The industrial manufacturing process covered by these patents is particularly innovative because it makes it possible to produce the main active ingredient QGC001 very efficiently in the form of single enantiomer. This process meets all the pharmaceutical requirements to industrialise the manufacturing of the product.
Fabrice Balavoine, Vice President Research & Development at Quantum Genomics, states:
“The granting of this new patent by the United States Office considerably enhances our intellectual property portfolio for our flagship product, QGC001. It makes it possible to provide and protect the industrialisation of the drug candidate in one of our key target markets. The industrial protection achieved meets the expectations of the world's leading laboratories with regard to large-scale manufacturing.”
 Armenia, Azerbaijan, Belarus, Russian Federation, Kazakhstan, Republic of Moldavia, Kirghizstan, Tajikistan, Turkmenistan.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance et communication
+33 1 53 67 36 73
|ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).